DAB2IP Attenuates Chemoresistance of Triple-negative Breast Cancer Through Sequestration of RAC1 to Prevent β-catenin Nuclear Accumulation

Overview

Journal Clin Transl Med

Publisher Wiley

Specialty General Medicine

Date 2022 Dec 19

PMID 36536485

Authors

Zhenchong Xiong

Lin Yang

Ning Li

Jianchang Fu

Peng Liu

Peng Sun

Weidong Wei

Xiaoming Xie

Affiliations

Soon will be listed here.

Abstract

Background: Although chemotherapy, the most widely used systemic treatment in triple-negative breast cancer (TNBC), markedly improved the patients' outcome, chemoresistance always occurs. This study purposed to explore new therapeutic strategies for the treatment of chemoresistance.

Methods And Results: The expression and prognostic value of DAB2IP were investigated in TNBC tissues and cell lines. Low DAB2IP expression predicted high mortality risk in TNBC. Inhibition of DAB2IP expression conferred cancer stem cell capacity and chemoresistance in TNBC cell lines. Using murine breast cancer (BC) xenograft models, we evaluated the association with DAB2IP and chemoresistance. DAB2IP inhibited TNBC tumourigenesis and chemoresistance in vivo. Further, we revealed that DAB2IP inhibited β-catenin nuclear transport through competitive interaction with RAC1 and decreased β-catenin accumulation in the cell nucleus. Finally, we found that the DNA methylation level was negatively associated with DAB2IP expression in TNBC. Inhibition of DNA methylation restored the DAB2IP expression and attenuated chemoresistance in TNBC.

Conclusions: We revealed that DAB2IP attenuates chemoresistance of TNBC via inhibition of RAC1-mediated β-catenin nuclear accumulation. Decitabine treatment results in re-expression of DAB2IP by inhibiting DNA methylation and could be a potential therapeutic strategy for chemoresistance in TNBC.

Citing Articles

An update on the tumor-suppressive functions of the RasGAP protein DAB2IP with focus on therapeutic implications.

De Florian Fania R, Bellazzo A, Collavin L Cell Death Differ. 2024; 31(7):844-854.

PMID: 38902547 PMC: 11239834. DOI: 10.1038/s41418-024-01332-3.

The scaffold protein disabled 2 (DAB2) and its role in tumor development and progression.

Pandya D, Parikh R, Gena R, Kothari N, Parekh P, Chorawala M Mol Biol Rep. 2024; 51(1):701.

PMID: 38822973 DOI: 10.1007/s11033-024-09653-9.

Disable 2, A Versatile Tissue Matrix Multifunctional Scaffold Protein with Multifaceted Signaling: Unveiling Role in Breast Cancer for Therapeutic Revolution.

Shah N, Dave B, Shah K, Shah D, Maheshwari K, Chorawala M Cell Biochem Biophys. 2024; 82(2):501-520.

PMID: 38594547 DOI: 10.1007/s12013-024-01261-5.

Disabled-2, a versatile tissue matrix multifunctional scaffold protein with multifaceted signaling: Unveiling its potential in the cancer battle.

Shah N, Dave B, Shah K, Shah D, Maheshwari K, Chorawala M Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(8):5533-5557.

PMID: 38502243 DOI: 10.1007/s00210-024-03037-3.

Endoplasmic reticulum stress in breast cancer: a predictive model for prognosis and therapy selection.

Yang B, Wang S, Yang Y, Li X, Yu F, Wang T Front Immunol. 2024; 15:1332942.

PMID: 38440732 PMC: 10910050. DOI: 10.3389/fimmu.2024.1332942.

References

Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C . let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007; 131(6):1109-23. DOI: 10.1016/j.cell.2007.10.054. View

Wolff A, Hammond M, Allison K, Harvey B, Mangu P, Bartlett J . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 36(20):2105-2122. DOI: 10.1200/JCO.2018.77.8738. View

Connolly R, Li H, Jankowitz R, Zhang Z, Rudek M, Jeter S . Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res. 2016; 23(11):2691-2701. PMC: 5457329. DOI: 10.1158/1078-0432.CCR-16-1729. View

Pfaffl M . A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29(9):e45. PMC: 55695. DOI: 10.1093/nar/29.9.e45. View

Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L . Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021; 6(1):307. PMC: 8403677. DOI: 10.1038/s41392-021-00701-5. View

Braso-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E . PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med. 2016; 22(11):1303-1313. PMC: 5552044. DOI: 10.1038/nm.4198. View

Min J, Liu L, Li X, Jiang J, Wang J, Zhang B . Absence of DAB2IP promotes cancer stem cell like signatures and indicates poor survival outcome in colorectal cancer. Sci Rep. 2015; 5:16578. PMC: 4643237. DOI: 10.1038/srep16578. View

Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, Doihara H . Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res. 2004; 10(6):2082-9. DOI: 10.1158/1078-0432.ccr-03-0236. View

10.

Hu Y, Smyth G . ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009; 347(1-2):70-8. DOI: 10.1016/j.jim.2009.06.008. View

11.

Olsen S, Wronski A, Castano Z, Dake B, Malone C, De Raedt T . Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers. Cancer Discov. 2016; 7(2):202-217. PMC: 6461361. DOI: 10.1158/2159-8290.CD-16-0520. View

12.

Lytle N, Barber A, Reya T . Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer. 2018; 18(11):669-680. PMC: 8388042. DOI: 10.1038/s41568-018-0056-x. View

13.

Li L, Dahiya R . MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002; 18(11):1427-31. DOI: 10.1093/bioinformatics/18.11.1427. View

14.

Tsai H, Li H, Van Neste L, Cai Y, Robert C, Rassool F . Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012; 21(3):430-46. PMC: 3312044. DOI: 10.1016/j.ccr.2011.12.029. View

15.

Wu X, Tu X, Joeng K, Hilton M, Williams D, Long F . Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell. 2008; 133(2):340-53. PMC: 2390926. DOI: 10.1016/j.cell.2008.01.052. View

16.

Xiong Z, Yang L, Li N, Fu J, Liu P, Sun P . DAB2IP attenuates chemoresistance of triple-negative breast cancer through sequestration of RAC1 to prevent β-catenin nuclear accumulation. Clin Transl Med. 2022; 12(12):e1133. PMC: 9763535. DOI: 10.1002/ctm2.1133. View

17.

Johnson S, Chen H, Lo P . Tumorsphere Formation Assays. Bio Protoc. 2016; 3(3). PMC: 4972326. DOI: 10.21769/bioprotoc.325. View

18.

Lu H, Clauser K, Tam W, Frose J, Ye X, Eaton E . A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol. 2014; 16(11):1105-17. PMC: 4296514. DOI: 10.1038/ncb3041. View

19.

Parida S, Wu S, Siddharth S, Wang G, Muniraj N, Nagalingam A . A Procarcinogenic Colon Microbe Promotes Breast Tumorigenesis and Metastatic Progression and Concomitantly Activates Notch and β-Catenin Axes. Cancer Discov. 2021; 11(5):1138-1157. DOI: 10.1158/2159-8290.CD-20-0537. View

20.

Batlle E, Clevers H . Cancer stem cells revisited. Nat Med. 2017; 23(10):1124-1134. DOI: 10.1038/nm.4409. View